Topics

Companies Related to "Data from Teprotumumab Phase OPTIC Study Shows Significantly" [Most Relevant Company Matches] RSS

20:58 EST 22nd November 2019 | BioPortfolio

Here are the most relevant search results for "Data from Teprotumumab Phase OPTIC Study Shows Significantly" found in our extensive corporate database of over 50,000 company records.

Showing "Data from Teprotumumab Phase OPTIC Study Shows Significantly" Companies 1–25 of 4,200+

Extremely Relevant

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...


Relevant

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...


Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

Atlantic Life Sciences, Inc

Atlantic Life Sciences, Inc., Provider of Tailored Clinical Services ALS Inc. is located in Montreal.It is one of the world-class CRO where the Experience, the Expertise and the Strategic Project Management create a value addition for the study success. Since its inception, Atlantic Life Sciences Inc. accomplishes clinical studies with a top quality. Each study is unique. Since 2003, ALS Inc. cond...

InnoPharm Limited

InnoPharm Ltd. is an independent Russian domestic contract research organization providing Phase II-IV clinical trials support. InnoPharm was established in 1991 and operates in Russia (mainly its European part), Ukraine and Belarus. We also perform data management and statistical processing of data generated in clinical studies conducted all over the world and organize regular and ad-hoc GCP semi...

Northwest Kinetics Incorporated

Northwest Kinetics is an independent research facility which specializes in Phase I and Phase II clinical pharmaceutical studies. Northwest Kinetics provides a full range of services for both short and long-term Phase I and II trials. Our services can include review of protocol design, pharmacokinetic consultation, patient recruitment, study execution, data management and record keeping, and repor...

Allegro Ophthalmics, LLC,

Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Allegro’s lead investigational drug risuteganib (Luminate®) successfully completed two Phase 2 diabetic macular edema (DME) studies and is currently being evaluated in a U.S. ...

Adamis Pharmaceuticals Corporation

La Jolla Pharmaceutical Company is a biopharmaceutical company. La Jolla had historically focused substantially all of its research, development and clinical efforts and financial resources toward the development of its Riquent® (abetimus sodium) product candidate, as a treatment for patients with lupus. In February 2009, La Jolla announced that an inde...

Convergence CT

Based in Honolulu, Hawaii, Convergence CT develops and markets highly secure patient data warehouse products, query tools, and patient data research analytics for the pharmaceutical, biotechnology, and healthcare industries. Emphasizing the ‘convergence’ of rich clinical data with advanced information technology and analysis, Convergence CT offers a ...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

ProFibrix B.V.

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant in development to stop bleeding after or during surgery. Fibrocaps is clearly differentiated from existing liquid tissue sealants and hemostats: it is ready for immediate use, is stable at room temperature, and has shown to be safe and efficacious...

RoMack Inc

RoMack is an established leader with decades of unique fiber optic experience. We supply fiber optic products that are superior in quality at any volume - from one-off to OEM. RoMack is all about forming long-lasting partnerships, which we do by never losing our customer service focus and by devoting value-added engineering to every fiber optic job. This ensures that your problem or product idea h...

Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Bost...

Trident Gum

Trident gum has long been a pioneer in providing oral health benefits to consumers. Trident was the first gum brand of its kind to undergo extensive long-term clinical testing in 1967 with studies showing that people who chewed Trident experienced significantly fewer cavities. Most recently, the brand introduced Trident Xtra Care(TM) with Recaldent®, a great tasting sugar free gum that delivers...

Phase Forward Incorporated

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Sc...

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

ARCH Clinical Research

ARCH Clinical Research provides pharmaceutical and biotechnology companies with high-quality clinical research services in Australia and New Zealand. In a time- and cost-efficient manner and according to the clients' exact needs, we can assist with completing the entire study or any segment, including: clinical study design, monitoring and management, data management and biostatistics, regulatory ...

GlycoMark, Inc.

GlycoMark is an FDA-cleared blood test that reveals repeated episodes of postprandial hyperglycemia/glycemic variability by tracking postprandial glucose levels as they related to blood levels of the molecule 1,5-anhydroglucitol (1,5-AG). Multiple published studies indicate that 1,5-AG detects hyperglycemia not detected by the hemoglobin A1C test. A recent study conducted as part of the internat...

Annexon Biosciences

Annexon’s pipeline of novel therapies includes two clinical-stage product candidates, ANX005, a monoclonal antibody, and ANX007, a fragmented monoclonal antibody, as well as other compounds in preclinical development. ANX005 is currently in a Phase 1/2 study in patients with Guillain-Barre Syndrome (GBS). Annexon also plans to evaluate ANX005 in complement-mediated neurodegenerative disorder...

Vaxin Inc.

Vaxin Inc. is a clinical stage biotechnology company, founded in December 1997 with facilities in Rockville, MD and Birmingham, AL, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technol...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...


More From BioPortfolio on "Data from Teprotumumab Phase OPTIC Study Shows Significantly"

Quick Search

Corporate Database Quicklinks